Identifying Patients with Undetected Gastro-oesophageal Cancer in Primary Care: External Validation of QCancer® (Gastro-Oesophageal)

Overview

Journal Eur J Cancer

Specialty Oncology

Date 2012 Nov 20

PMID 23159533

Citations 19

Authors

Gary S Collins

Douglas G Altman

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the performance of QCancer® (Gastro-Oesophageal) for predicting the risk of undiagnosed gastro-oesophageal cancer in an independent UK cohort of patients from general practice records.

Design: Open cohort study to validate QCancer® (Gastro-Oesophageal) prediction model. Three hundred sixty-five practices from the United Kingdom contributing to The Health Improvement Network database. 2.1 million patients registered with a general practice surgery between 01 January 2000 and 30 June 2008, aged 30-84years (3.7 million person years) with 1766 gastro-oesophageal cancer cases. The outcome, gastro-oesophageal cancer was defined as incident diagnosis of gastro-oesophageal cancer during the 2years after study entry.

Results: The results from this independent and external validation of QCancer® (Gastro-Oesophageal) demonstrated good performance data on a large cohort of general practice patients. QCancer® (Gastro-Oesophageal) had very good discrimination with c-statistics of 0.93 and 0.94 for women and men respectively. QCancer® (Gastro-Oesophageal) was well calibrated across all tenths of risk and over all age ranges with predicted risks closely matching observed risks. QCancer® (Gastro-Oesophageal) explained 74.4% and 75.6% of the variation in men and women respectively.

Conclusions: QCancer® (Gastro-Oesophageal) is a useful tool to identify undiagnosed gastro-oesophageal cancer in primary care in the United Kingdom.

Citing Articles

Protocol for a pragmatic cluster randomised controlled trial assessing the clinical effectiveness and cost-effectiveness of Electronic RIsk-assessment for CAncer for patients in general practice (ERICA).

Hamilton W, Mounce L, Abel G, Dean S, Campbell J, Warren F BMJ Open. 2023; 13(3):e065232.

PMID: 36940950 PMC: 10030284. DOI: 10.1136/bmjopen-2022-065232.

Machine Learning for Risk Prediction of Oesophago-Gastric Cancer in Primary Care: Comparison with Existing Risk-Assessment Tools.

Briggs E, de Kamps M, Hamilton W, Johnson O, McInerney C, Neal R Cancers (Basel). 2022; 14(20).

PMID: 36291807 PMC: 9600097. DOI: 10.3390/cancers14205023.

Artificial intelligence predictive system of individual survival rate for lung adenocarcinoma.

He T, Li J, Wang P, Zhang Z Comput Struct Biotechnol J. 2022; 20:2352-2359.

PMID: 35615023 PMC: 9123088. DOI: 10.1016/j.csbj.2022.05.005.

Barriers and facilitators to implementing a cancer risk assessment tool (QCancer) in primary care: a qualitative study.

Akanuwe J, Black S, Owen S, Siriwardena A Prim Health Care Res Dev. 2021; 22:e51.

PMID: 34615569 PMC: 8527274. DOI: 10.1017/S1463423621000281.

Conceptual Framework to Guide Early Diagnosis Programs for Symptomatic Cancer as Part of Global Cancer Control.

Koo M, Unger-Saldana K, Mwaka A, Corbex M, Ginsburg O, Walter F JCO Glob Oncol. 2021; 7:35-45.

PMID: 33405957 PMC: 8081530. DOI: 10.1200/GO.20.00310.